Evidence map›Paper›PMID 39164625›Full record

SynthesisBMC infectious diseases2024

Burden of respiratory syncytial virus (RSV) infection in Germany: a systematic review.

Anahita Poshtiban, Moritz Wick, Mathieu Bangert, Oliver Damm

Abstract readSystematic Review
In one paragraph

Synthesis in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Navigating parental hesitancy in public health: the case for RSV immunization in newborns.Journal of perinatology : official journal of the California Perinatal Association · 2025
    Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anahita PoshtibanSanofi-Aventis Deutschland GmbH, Lützowstr. 107, 10785, Berlin, Germany. anahita.poshtiban@sanofi.com.ORCID http://orcid.org/0000-0001-5190-5617
Moritz WickSanofi-Aventis Deutschland GmbH, Lützowstr. 107, 10785, Berlin, Germany.ORCID http://orcid.org/0000-0003-3032-6354
Mathieu BangertSanofi Vaccines, Lyon, France.ORCID http://orcid.org/0000-0003-1320-8145
Oliver DammSanofi-Aventis Deutschland GmbH, Lützowstr. 107, 10785, Berlin, Germany.ORCID http://orcid.org/0000-0003-0261-3655

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRespiratory syncytial virus (RSV) is a major cause of acute lower respiratory infection and hospitalizations among infants, young children, and the elderly. This systematic literature review aimed to summarize the epidemiological and economic burden estimates of RSV infection at any age in Germany.

methodsWe conducted a systematic literature search to identify full-text articles published from 2003 to 2023 and reporting data on the epidemiological or economic burden of RSV in Germany. Based on pre-specified eligibility criteria, data on incidence, rates of hospital and intensive care unit (ICU) admission, clinical manifestation, underlying conditions, seasonality, health care resource use and costs were extracted.

resultsAfter screening 315 full-text articles, we included 42 articles in the review. The characteristics of the included studies were heterogenous regarding study population, setting, age groups and RSV-related outcome measures. The most frequently reported epidemiological outcome measures were RSV detection rate (n = 33), followed by clinical manifestation (n = 19), seasonality (n = 18), and underlying conditions of RSV infection (n = 13). RSV detection rates were reported across heterogenous study populations, ranging from 5.2 to 55.4% in pediatric inpatient cases and from 2.9 to 14% in adult inpatient cases. All articles that reported RSV detection rates across several age groups demonstrated the highest burden in infants and young children. Few articles reported RSV-related outcome measures distinctively for the outpatient setting. Health care resource use, such as hospital length of stay, ICU admission rate and treatment of patients with RSV infection were described in 23 articles, of which only one study quantified associated costs from 1999 to 2003 for children ≤ 3 years. In-hospital ICU admission rates varied between 3.6 and 45%, depending on population characteristics as age and underlying conditions.

conclusionsThis systematic review revealed that RSV imposes substantial disease burden in infants, young children, and the elderly in Germany, whereby infants are particularly affected. To date, there has been limited exploration of the impact of RSV infection on healthy children or the elderly in Germany. Given their notably high reported burden in studies, the medical and economic RSV burden in these groups should move more into focus.

Indexed as

Cost of IllnessHospitalizationRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsAdultAgedChildChild, PreschoolGermanyHealth Care CostsHumansIncidenceInfantIntensive Care UnitsSeasonsBronchiolitisDisease burdenGermanyResource use and costsRespiratory infectionRespiratory syncytial virus

Identifiers

PMID39164625
PMCPMC11337829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.